With hospitals at risk, Mass. eyes lifeline for broke insurer covering 460K public employees
Editor's note: Story was updated Thursday afternoon to include a statement from GIC.
Amid fears of 'serious financial consequences,' Massachusetts is working to create a lifeline for a Massachusetts agency that oversees health insurance for 460,000 public employees, retirees and their dependents after it could not continue to pay providers.
In January, state Group Insurance Commission (GIC) Executive Director Matthew Veno had flagged the agency's budget shortfalls as a concern.
'This is the largest variance that we've seen in at least a decade, and this is consistent across all of our plans, and is driven primarily by rising provider prices and a couple of other topics,' he said at the time. 'We don't know where this is going to head. My concern is that it is a persistent and steady trend going forward.'
Then in April, Veno said rising provider prices and increased utilization of prescription benefits, including for GLP-1 weight loss drugs, had caused the commission to run an average $20 million monthly deficit this fiscal year.
Massachusetts Health & Hospital Association (MHA) said it was 'unacceptable' for the insurance agency to have a lack of backup options and claims the disruption in payments 'will undoubtedly result in serious financial consequences.'
Read more: Mass. health insurance companies directed to limit growth of deductibles, copays
Mercy Medical Center in Springfield said it 'is not in a financial position to absorb budget shortfalls of the state Massachusetts Group Insurance Commission.'
'While we appreciate the financial situation of the GIC, we join them in advocating for funding to resolve its budget deficiency that will not further exacerbate the financial condition of healthcare providers,' the statement continued.
But the Massachusetts Legislature didn't act before GIC officially ran out of money on Monday. All claims have remained pending since then.
The commission had been counting on a $237 million appropriation request before the Legislature.
The appropriation was the largest single request in a $756 million short-term spending bill Gov. Maura Healey filed in early April.
However, in an email sent to providers earlier this month, the GIC warned that it 'does not know how soon the legislature will pass the bill and when the GIC will receive the requested funds.'
The claims will remain pending until GIC receives the additional funds or until July 1.
This week, Massachusetts began moving forward on the requested funds.
The House advanced a $240 supplemental budget for the agency on Monday. And the Senate passed it on Thursday.
'Ensuring that the hundreds of thousands of public employees and their loved ones have access to health insurance is one of our most important responsibilities,' said Senate President Karen E. Spilka, D-Middlesex/Norfolk.
Now it is set for Healey's desk.
'The GIC is grateful to the House and Senate for passing the Governor's supplemental budget request. We look forward to lifting the hold on claims payments and promptly resuming payment of pended claims following the Governor's signature of the legislation,' GIC said in a statement to MassLive. 'We appreciate the patience of plans and providers as we worked toward resolution in a way that would minimally impact our members.'
But this isn't unique to GIC.
'The Group Insurance Commission is facing a challenge that is not unique to any insurer, as pharmaceutical usage is going up and the costs of drugs are rising at an unsustainable rate,' said Senator Cindy F. Friedman, D-4th Middlesex, the Senate's chair of the Legislature's Joint Committee on Health Care Financing.
'The Senate is actively working on measures to address this larger issue, as well as other cost drivers throughout the health care system, to relieve the pressure on insurers and the premiums that residents in the Commonwealth face,' the Arlington lawmaker continued. 'As we work towards the end goal of stabilizing health care costs, this supplemental funding for the GIC will ensure that our state employees stay covered and healthy.'
Mass. health insurance companies directed to limit growth of deductibles, copays
'Unacceptable': Health insurer for 460K Mass. public workers goes broke without backup plan
Insurance program for 460,000 Mass. residents runs out of money Monday
Read the original article on MassLive.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
PepsiCo Leans on Gatorade & LIFEWTR: Can Wellness Fuel Growth?
PepsiCo, Inc.'s PEP hydration portfolio is anchored by Gatorade and LIFEWTR, two brands that reflect its strategic shift toward functional performance and premium wellness offerings. In first-quarter 2025, Gatorade remained a strong performer, especially with innovations like Gatorade Zero and new rapid hydration products. The company is also investing in powders, tablets and other functional hydration options to meet evolving health and wellness demands. Gatorade's ongoing expansion into performance-focused formats is helping it regain its share in the competitive sports drink PepsiCo's premium bottled water brand, is another pillar of the company's health-focused strategy. Positioned as a wellness-driven offering, LIFEWTR taps into the growing consumer interest in premium hydration with clean ingredients and lifestyle-oriented branding. The brand's continued double-digit growth demonstrates strong traction, supporting PepsiCo's broader efforts to diversify away from traditional sugary beverages. This approach aligns with the company's intention to offer more permissible, functional beverages across a range of consumer these efforts is PepsiCo's broader shift toward 'better-for-you' portfolios, which include investments in protein, fiber and reduced sugar offerings. Notably, the company is innovating in protein-enriched beverages and snacks, aiming to capture value in emerging consumption trends, such as those driven by GLP-1 medication users seeking smaller portions and nutrient-dense foods. With consumer demand moving toward healthier, more functional products, PepsiCo's strategy of doubling down on brands like Gatorade and LIFEWTR positions it well for sustained growth in the wellness space. The Coca-Cola Company KO and Keurig Dr Pepper KDP are the key beverage companies competing with PepsiCo in the global Coca-Cola Company is strategically reinforcing its hydration and wellness lineup to compete directly with PepsiCo's Gatorade and LIFEWTR by leveraging brands like Powerade, Smartwater and Vitaminwater. Powerade has been revamped with a focus on innovation in performance hydration, incorporating enhanced electrolytes and new formulations to target athletes and fitness enthusiasts. Smartwater and Vitaminwater continue to lead Coca-Cola's charge in the premium and functional beverage segments, respectively, offering vapor-distilled purity and added nutrients. The company is also investing in digital marketing, packaging personalization and local relevance campaigns to build consumer trust and loyalty. With 30 billion-dollar brands in its portfolio and 68% of its drinks containing fewer than 100 calories per serving, Coca-Cola is aligning with health trends through innovation and consumer-centric strategies, positioning itself as a strong challenger to PepsiCo's hydration Dr Pepper competes aggressively with PepsiCo in the hydration and wellness space through brands like Core Hydration and Snapple Elements, focusing on functional benefits and health-conscious positioning. KDP's strategy centers on leveraging consumer trends such as low-calorie, antioxidant-rich and pH-balanced beverages, positioning Core as a premium hydration brand. Innovation remains a cornerstone of its approach, with ongoing flavor expansions, clean-label formulations and sleek packaging aimed at wellness-driven Millennials and Gen Z consumers. By capitalizing on its broad distribution network and agile marketing, KDP is carving out a strong niche against PepsiCo's Gatorade and LIFEWTR, appealing to consumers looking for alternatives with perceived health benefits and contemporary branding. Shares of PepsiCo have lost around 14.5% year to date against the industry's growth of 7.6%. Image Source: Zacks Investment Research From a valuation standpoint, PEP trades at a forward price-to-earnings ratio of 16.13X, significantly below the industry's average of 18.68X. Image Source: Zacks Investment Research The Zacks Consensus Estimate for PEP's 2025 earnings implies a year-over-year decline of 3.6%, whereas its 2026 earnings estimate suggests year-over-year growth of 5.4%. The estimates for 2025 and 2026 have been southbound in the past 30 days. Image Source: Zacks Investment Research PEP stock currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CocaCola Company (The) (KO) : Free Stock Analysis Report PepsiCo, Inc. (PEP) : Free Stock Analysis Report Keurig Dr Pepper, Inc (KDP) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Odyssey bails on public listing as US IPO landscape stutters
Odyssey Therapeutics is unlikely to join the 2025 class of biotechs hitting the stock exchanges after the company withdrew its registration statement for an initial public offering (IPO). The autoimmune and inflammatory disease specialist was one in a wave of biotechs to reveal IPO ambitions in January 2025. While Sionna Therapeutics, a biopharma that filed IPO paperwork at the same time, went on to close a nearly $220m IPO in February, Odyssey has bailed on a public listing. Odyssey did not disclose the number of its common stock shares it was offering, nor the price at which the IPO would conduct on each share. The Form S-1, a registration form with the US Securities and Exchange Commission (SEC) for companies carrying out public offerings, only mentioned that the listing would have occurred on the Nasdaq. Odyssey was eyeing an IPO as a way to fund its pipeline, headed by RIPK2 inhibitor OD-07656 that was set for Phase II trials for ulcerative colitis treatment, both as a monotherapy and in combination with Takeda's blockbuster Entyvio (vedolizumab). As per its IPO prospectus in January, the monotherapy trial was set to commence in Q1 2025, with the combo trial slated for the same quarter in 2026. Two pre-clinical programmes also stood to benefit from cash generated from the IPO. In its notice to the SEC outlining the withdrawal of the registration statement, Odyssey stated it is because it is 'not in the best interests of the company to conduct the proposed offering at this time'. The IPO U-turn is the first sign that the health of the IPO landscape could be suffering in the wake of economic fallout from US President Donald Trump's policies. Indeed, it consolidates predictions made by one GlobalData analyst earlier this year. In April, GlobalData business fundamentals analyst Alison Labya said: 'The Trump administration has introduced uncertainty to the biopharmaceutical industry across healthcare policies, drug pricing reforms, and regulatory frameworks, all of which could impact investor confidence. 'Additionally, Trump's recent tariff announcement on imports from Canada, Mexico, and China has led to increased market volatility, potentially delaying IPOs as investors await the countries' responses to the tariffs.' Biotech IPOs saw a strong recovery in 2024, with a total raise of $8.52bn, up 68.4% from $5.06bn raised in 2023. It was the highest total IPO value raised since 2021, with the rebound driven by US Federal Reserve interest rate cuts. The uptick continued into 2025, with Sionna joined by Maze Therapeutics and Metsera Therapeutics. U-turning on IPOs is rare, but Odyssey is not the only biotech to bail on a public listing in the past year. Australian biotech Telix Pharmaceuticals withdrew its US public listing at the last minute in June 2024, also citing unfavourable market conditions at the time. "Odyssey bails on public listing as US IPO landscape stutters" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio


Newsweek
2 hours ago
- Newsweek
GOP Candidate Says Number of Women on Birth Control 'Concerning'
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A Minnesota GOP Senate candidate has said that he finds the number of women on birth control "concerning" because the pills not only change female hormones but also change the kind of men women are attracted to. Adam Schwarze told Heartland Signal, a local radio show reporting predominantly in the Midwest, that birth control was making women more attracted to "beta" men as opposed to "alpha cavemen." Newsweek has contacted Schwarze via social media for comment. Why It Matters Access to birth control and reproductive rights has come into the spotlight since President Donald Trump started his second term as president, and requests for contraceptives, including long-term birth control and "morning after" pills and abortion pills, soared after his election victory. After Roe v Wade was overturned by Republican-appointed Supreme Court justices, taking the constitutional right to abortion away from American women, concerns about what the Trump administration's plans are for reproductive rights have been escalating. While the Republican base in America is comprised of a large proportion of religious groups, particularly evangelical Christians and Catholics, who oppose birth control, a 2024 Navigator Research survey found that 74 percent of Americans believed birth control should be easier to access. File photo: birth control pills. File photo: birth control pills. Serge Pouzet/Sipa via AP What To Know Schwarze also told Heartland Signal that because of the influence birth control pills are having on women and their attractions, U.S. society as a whole is becoming more "pacified." "It's actually kind of concerning because it's changing our culture and values because of birth control," he said, adding it was "fascinating but also scary." Saying that a lot of women are now using birth control, he added: "We are changing our society away from men who are alphas, providers, protectors, doers, builders for these effeminate girly boys." According to research by KFF last year, 82 percent of American women of reproductive age reported having used some form of contraception in the past 12 months. There are some studies that have indicated the birth control pill, i.e. an oral contraceptive, could influence what features women are attracted to in men, with one 2013 study finding that "initiation of pill use significantly decreased women's preferences for male facial masculinity." A 2011 study also investigated the relationship outcomes of women using the pill but stated that "we know neither whether these laboratory-measured effects are sufficient to exert real-world consequences, nor what these consequences would be." The reasons behind possible changes to attraction have been attributed to female hormone levels, however there is still limited research on the subject and more rigorous studies are needed in order to determine whether birth control changes what kind of men women are attracted to. What People Are Saying Minnesota GOP Senate candidate Adam Schwarze said during a radio interview with Heartland Signal: "There is a study that's getting popularity and more widely known that women on birth control, it actually changes your hormones and your attractions, so women who are on birth control, and this is more Democrats who are on birth control than conservatives because of some religious reasons, but it actually changes who you are attracted to and there's multiple reports on this, ... of girls who leave birth control when they want to start families or just decide to do a different method of pregnancy prevention, that they leave their partners because they are not attracted to them because birth control makes you attracted to betas." What Happens Next The Trump administration has passed an executive order to prevent federal funding of elective abortion, alongside ending "the forced use of federal taxpayer dollars to fund or promote elective abortion," however, it is not yet clear if the administration plans to alter women's access to birth control.